Satellite Symposium Advanced Accelerator Applications, A Novartis Company Friday, October 30, 13:50-15:20 Channel 4 Session Title Evolution of theragnostics and targeted therapies for advanced prostate cancer: the role of the multidisciplinary team Objectives:
• Explore the treatment landscape and unmet need in advanced prostate cancer • Discuss the new targeted treatment options in development for advanced prostate
cancer, including radioligand therapy, poly-ADP ribose polymerase inhibitors (PARPi), and other targeted modalities
• Review the role of the nuclear medicine physician in the management of advanced prostate cancer patients
• Discuss the importance of MDT collaboration to achieve the best outcomes for advanced prostate cancer patients
Chairperson: Prof. Joe O’Sullivan Speakers: Prof. Bertrand Tombal Dr. Daniel Heinrich Prof. Dr. med. Ken Herrmann
Lecture time: 5 min Welcome and introduction
Chair: Prof. Joe O’Sullivan
Lecture time: 20 min Current treatments and unmet needs in advanced
prostate cancer
Speaker: Prof. Bertrand Tombal
Lecture time: 20 min
Advanced targeted therapies on the radar
Speaker: Prof. Joe O’Sullivan
Lecture time: 20 min
Role of the nuclear medicine physician in the management of advanced prostate cancer patients
Speaker: Prof. Dr. med. Ken Herrmann
Lecture time: 15 min Case study: The role of the MDT in treatment
decisions and patient follow-up
Speaker: Dr. Daniel Heinrich
Lecture time: 10 min
Panel discussion
Chair: Prof. Joe O’Sullivan Panel: Prof. Bertrand Tombal, Dr. Daniel Heinrich, and Prof. Dr. med. Ken Herrmann
